Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glaucoma study reveals how quickly early cases worsen

NCT ID NCT03394521

Knowledge-focused Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study followed 326 people newly diagnosed with glaucoma or high eye pressure to see how many got worse over 2 to 4 years of standard monitoring in hospital eye clinics. Researchers measured the rate of disease progression and looked for factors that might predict worsening. No new treatments were tested; the goal was simply to understand the natural course of early glaucoma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

326 people

The number who actually took part.

Start date

Oct 2015

Finished

Aug 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort of patients identified through the GATE study - newly referred from community to hospital eye services with suspected glaucoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility for patients to be recruited into the GATE study was as follows: Inclusion criteria: \- Adults referred from community optometrists or general practitioner to hospital eye services with suspected glaucoma, including those with ocular hypertension. Exclusion criteria: * Patients referred to hospital eye services because of other ocular disease; * patients \< 18 years old; * patients who cannot give informed consent, * patients already diagnosed with glaucoma. This study cohort is further defined from the GATE population as Selection criteria: * GATE study patients with a baseline diagnosis of OHT, Glaucoma suspect or Glaucoma (any mechanism); * remaining in secondary care monitoring after first visit; * recruited at Aberdeen Royal Infirmary or Hinchingbrooke Hospital NHS Trust.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disease Progression glaucoma ocular hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

More trials for these conditions

Other studies related to the condition(s) this trial covers.